Why Choose Between SGLT2 Inhibitors and GLP1-RA When You Can Use Both?: The Time to Act Is Now

Circulation. 2021 Feb 23;143(8):780-782. doi: 10.1161/CIRCULATIONAHA.120.053058. Epub 2021 Feb 22.

Author

Alice Y Y Cheng¹

Affiliation

¹ Division of Endocrinology and Metabolism, Department of Medicine, Trillium Health Partners and Unity Health Toronto, University of Toronto, Canada.

PMID: 33617314
DOI: 10.1161/CIRCULATIONAHA.120.053058

No abstract available

Keywords: Editorials; glucagon-like peptide receptors; sodium-glucose transporter 2 inhibitors.

Publication types

Editorial
Comment

MeSH terms

Glucagon-Like Peptide-1 Receptor
Humans
Hypoglycemic Agents / adverse effects
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors